Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Long-Term Debt Repayments (2020 - 2022)

Theravance Biopharma (TBPH) has disclosed Long-Term Debt Repayments for 3 consecutive years, with -$168.4 million as the latest value for Q4 2022.

  • Quarterly Long-Term Debt Repayments changed N/A to -$168.4 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was -$163.4 million through Dec 2022, down 1622.47% year-over-year, with the annual reading at $231.6 million for FY2022, 2058.48% up from the prior year.
  • Long-Term Debt Repayments for Q4 2022 was -$168.4 million at Theravance Biopharma, down from $5.0 million in the prior quarter.
  • The five-year high for Long-Term Debt Repayments was $235.3 million in Q1 2020, with the low at -$168.4 million in Q4 2022.
  • Average Long-Term Debt Repayments over 3 years is $19.4 million, with a median of $5.4 million recorded in 2021.
  • Peak annual rise in Long-Term Debt Repayments hit 97.58% in 2021, while the deepest fall reached 97.58% in 2021.
  • Over 3 years, Long-Term Debt Repayments stood at $235.3 million in 2020, then plummeted by 97.86% to $5.0 million in 2021, then crashed by 3446.44% to -$168.4 million in 2022.
  • According to Business Quant data, Long-Term Debt Repayments over the past three periods came in at -$168.4 million, $5.0 million, and $5.7 million for Q4 2022, Q2 2021, and Q1 2021 respectively.